Analysts cut target for Smith+Nephew stock to GBp 1,257.00 from GBp 1,291.00

Published on 10/13/2026 at 07:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue reached USD 3.10 billion, up 4.60 percent year over year. Smith+Nephew stock was last at EUR 12.35 on October 12, 2026, before November 4 results.

Key points in brief

Analysts cut the Smith+Nephew price target to GBp 1,257.00 from GBp 1,291.00 on September 7, 2026.
First-half 2026 revenue reached USD 3.10 billion, up 4.60 percent year over year.
Smith+Nephew was last at EUR 12.35 at Lang & Schwarz on October 12, 2026.
The company will release third-quarter 2026 results on November 4, 2026.

Aquarell einer britischen Flusspromenade mit Bürogebäuden und Kirchturm — Smith & Nephew plc (ISIN GB0009223206) hat seinen Firmensitz in Watford, dargestellt als stimmungsvolles Aquarellbild, Illustration mit AI erstellt.

Analysts cut the Smith+Nephew price target to GBp 1,257.00 from GBp 1,291.00 in a September 7, 2026 update, while first-half revenue reached USD 3.10 billion, up 4.60 percent year over year. Simply Wall St linked the target change to revised assumptions for revenue growth, profit margins and valuation.

Target cut meets fresh product launches

Smith+Nephew launched the CARTIHEAL AGILI-C Cartilage Repair Implant in Europe on October 6, 2026. The launch covers Austria, Belgium, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, Switzerland and the United Kingdom.

The latest reported period was the first half of 2026, covering the six months ended June 27. Revenue was USD 3.10 billion, while trading profit reached USD 566.00 million and trading profit margin expanded to 18.30 percent, according to the investor materials.

Three dated milestones shape the story

On June 9, 2026, Smith+Nephew announced the first clinical cases using its CORI XT handheld robotic platform across knee and shoulder procedures. On September 22, it reported FDA 510(k) clearance and the first surgical cases for the LANDMARK Total Knee System. On October 6, it launched CARTIHEAL AGILI-C in Europe.

Those milestones point to a portfolio strategy built around robotics, implants and wound care rather than a single product cycle. The company operates through Advanced Wound Management, Sports Medicine and ENT, and Orthopaedics.

What dates matter for investors?

The company scheduled its third-quarter 2026 results for November 4, 2026, with the release set for 7:00 a.m. GMT. The investor calendar also lists the presentation from 12:00 p.m. GMT on the same date, according to Smith+Nephew.

For the first half of 2026, reported revenue growth of 4.60 percent contrasts with the reduced full-year underlying growth outlook of 4.00 percent. The company expects second-half underlying revenue growth of 5.00 percent to 5.50 percent, making the November report the next test of that recovery path.

Stock stays tied to the next report

The last available Lang & Schwarz quote was EUR 12.35 on October 12, 2026 at 11:00 p.m. CEST. Smith+Nephew is listed on the London Stock Exchange, where the ordinary shares trade under the symbol SN. The London listing is identified in a September 18, 2026 filing by the SEC.

The further course of trading is shown by the continuously updated real-time quote of Smith+Nephew stock.